COMPANY:

SeekIn

"SeekIn Inc...announced CE (Conformité Européenne) Mark approval for PanCanSeek® Cancer Mutation Detection Kit and is now ready to launch this test in European Union and other countries that recognize CE-IVD Mark...PanCanSeek® is developed as the world's first integrated solution for leukemia cytogenetics and molecular diagnostics. It uses high-depth WGS, which can cover four different detection techniques – karyotyping for CNV, FISH for gene fusion, qPCR for single mutation and targeted NGS panel for multiple mutations."

"SeekIn Inc...today announced CE (Conformité Européenne) Mark approval for SeekInCure Cancer Recurrence Monitoring Kit and is now ready to launch this test in European Union and other countries that recognize CE-IVD Mark."

"SeekIn Inc...announced the results of the pan-cancer/pan-indication treatment response monitoring test, SeekInClarity®, which were presented at the AMP 2022 Annual Meeting & Expo in Phoenix, Arizona, United States...study presents a strong demonstration that SeekInClarity can be considered an in vivo drug sensitivity test."

"SeekIn Inc...announced the results of pan-cancer early detection test SeekInCare® were presented at The 2022 Early Detection of Cancer Conference in Portland, Oregon."

"SeekIn Inc...announced CE (Conformité Européenne) Mark approval for OncoSeek® Multi-Cancer Detection Test and is now ready to launch this test in European Union and other countries that recognize CE mark...OncoSeek®, a customized panel of seven selected protein tumor markers (PTMs) including AFP, CA125, CA15-3, CA19-9, CA72-4, CEA, and CYFRA21-1, quantified them on Roche cobas e411 instrument performing for 12 common cancers early detection."

"SeekIn said...that it has received CE marking for its SeekInClarity Cancer Treatment Response Monitoring Kit...The Shenzhen, China-based biotech said that it is now ready to launch the kit in Europe and other countries that recognize the CE mark...The liquid biopsy assesses cancer treatment response through changes in circulating tumor DNA."

"SeekIn said on Thursday that it has received CE marking for its LeukoPrint Molecular Karyotyping Kit for the diagnosis and stratification of leukemia patients...LeukoPrint uses shallow whole-genome sequencing to identify copy number aberrations (CNA) in blood samples from leukemia patients to assist in diagnostic classification and risk stratification."

"SeekIn Inc...announced the CE (Conformité Européenne) Mark for SeekInCare® Cancer Detection Kit and is now ready to launch this test in European markets."